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1. Introduction
MicroRNAs  (miRNAs)  are  small  non-coding  RNAs  of  approximately  22  nucleotides  in
length, whose main function is to modulate the expression of multiple target genes at the
post-transcriptional  level  through messenger-RNA (mRNA) degradation or repression of
translation [1-3]. More than 30% of all human genes are regulated by miRNAs, with each
miRNA controlling  multiple  mRNA targets,  and each  mRNA targeted  by  various  miR‐
NAs [2]. These intriguing molecules has been first described in 1993 in Caenorhabditis ele‐
gans  [4] and first demonstrated in humans in 2001 [5]. Since then, several miRNAs have
been  identified  and  more  than  2.042  miRNAs  have  been  described  in  humans  to  date
(miRBase release 19, at http:// www.mirbase.org/).
MiRNA play a crucial role in modulating a large range of biologic functions from develop‐
mental timing to organogenesis [6,7]. They have a key role in cellular differentiation, homeo‐
stasis, apoptosis and anti-viral defence [1,8]. More recently, it has become evident that
miRNAs play a crucial role in the development of immune cells and in regulating the im‐
mune response [9-11].
Altered expression of miRNAs profiles has been initially related to the development of can‐
cer and subsequently to various non-malignant diseases such as cardiovascular disorders,
lung diseases, schizophrenia, Alzheimer disease, neuro psychiatric disorders, viral infec‐
tions, primary biliary cirrhosis and chronic inflammatory and autoimmune diseases [12-17]
In the last two decades, increasing evidences have linked miRNA abnormal expression with
pathogenic mechanisms of cancer, and a lot of causes that led to their dysregulation have
been discovered [18]. Many miRNAs have been associated with cancer development [19,20],
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metastatic capability [21] and resistance to anti-cancer drugs [22]. In this field, they are also
considered as new potential diagnostic and prognostic biomarkers [20, 23]. Furthermore the
application of miRNAs as a candidate molecular target for anticancer therapeutics seems
very promising [18,24].
More recently, some studies have highlighted the role of miRNAs in the development of sever‐
al rheumatic diseases [25-33]and this argument today represents an emerging and exciting
field of research. This is not surprising since miRNAs altered expression may lead either to per‐
sistent inflammation or to impaired tolerance against self-antigens, thus promoting the devel‐
opment of both autoimmune and inflammatory chronic diseases [11, 34].
In this article we summarize the new acquisitions about the growing importance of miRNAs
in rheumatic diseases as pathogenetic factors, potential biomarkers and possible new thera‐
peutic targets. We also focus on new developments about the possible role of miRNA in the
pathogenesis of psoriatic arthritis (PsA) on the basis of our recent experimental results.
2. MiRNAs in rheumatic diseases
2.1. Connective tissue disorders
2.1.1. Systemic lupus erythematosus
Systemic lupus erithematosus (SLE) is an autoimmune systemic disease of unknown etiolo‐
gy characterized by abnormal autoantibody production, inflammatory involvement of vari‐
ous organ systems including skin, mucous membranes, joints, serous membranes, kidney,
brain, lung and heart and significant morbidity and mortality [35].A number of studies car‐
ried out so far, have demonstrated that miRNA have an important role in SLE pathogenesis
and can be predictive of disease activity and severity, helpful as biomarkers and useful for
development of new therapeutic strategies [36-42].
In the study of Dai et al. [36], peripheral blood mononuclear cell (PBMC) miRNA profiles
of 23 patients with SLE, 10 healthy controls and 10 patients with idiopathic thrombocyto‐
penic purpura (ITP) were analyzed. In comparison with healthy controls, miRNA microar‐
ray analysis identified 19 miRNA differentially expressed in ITP (14 down-regulated and 5
up-regulated) and 16 miRNAs differentially expressed in SLE (7 down-regulated: miR-196a,
miR-17-5p,  miR-409-3p,HMP-PREDICTED-miR141,  miR-383,  HMP-PREDICTED-miR112
and  miR-184;  and  9  up-regulated:  HMP-PREDICTED-miR189,  HMP-PREDICTED-miR-61,
HMP-PREDICTED-miR78,  miR-21,miR-142-3p,  miR-342,  miR-299-3p,miR-198  and  mmu-
miR-298). Interestingly, from the comparison between the two pathologic groups,13 miR‐
NAs resulted dysregulated both in SLE and ITP, 6 downregulated in ITP only, and finally
3 dysregulated in  SLE only:  miR-184 (underexpressed)  and miR198 and miR21 (overex‐
pressed) [36].  Furthermore,  8 miRNA (miR-494,  miR-188,  miR-501,  mmu-miR-298,  HMP-
PREDICTED-miR61,  HMP-PREDICTED-miR78,  miR-296  and  miR-299-3p)  were
downregulated in SLE patients with more active disease (SLE Disease Activity Index score
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[SLEDAI] ≥15) in comparison with patients with inactive disease (SLEDAI ≤12), which led
to  hypothesized that  these  8  miRNA could be  involved in  SLE progress,  recrudescence
and organ injure [36]. The same group examined miRNA expression in renal biopsy of pa‐
tients with WHO Class II lupus nephritis (LN), showing 66 dysregulated miRNA (36 up-
and 30 down-regulated) in comparison with healthy controls [37].
Te et al. investigated PBMCs miRNA expression profile of LN patients (African American
and European American) in comparison with unaffected controls and found 5 miRNA dif‐
ferentially expressed in LN: 4 up-regulated (miR-371–5P, miR-423–5P, miR-638 and
miR-663) and 1 down-regulated (miR-1224–3P) [43]. In particular, miR-371-5P, miR-423-5P
and miR-1224-3P were reported for the first time to be associated with lupus nephritis [43].
In a study performed by using the TaqMan miRNA assay, Tang et al. showed in SLE PBMCs
42 miRNAs differentially expressed in comparison with healthy controls, with 7 miRNA be‐
ing more than six-fold down-regulated in SLE: miR-31, miR-95, miR-99a, miR-130b,
miR-10a, miR-134, and miR-146a [40]. Notably, underexpression of miR-146a negatively cor‐
related with clinical disease activity and with interferon (IFN) scores in SLE patients. More‐
over, inhibition of endogenous miR-146a in PBMCs through transfection with synthetic
miRNA-146a hairpin inhibitor increased the induction of type I IFN, which is known to
have a role in the pathogenesis of SLE. These findings highlighted that underexpression of
miR-146a could have an important role in the pathogenesis of SLE, thus providing potential
novel strategies for therapeutic intervention [40].
Consistent with these results, Wang et al. showed that in SLE patients serum miR-146a and
miR-155 levels were lower, and the urinary level of miR-146a was higher in comparison
with healthy controls [44]. Moreover, estimated glomerular filtration rate (eGFR) correlated
with both serum miR-146a and miR-155, and serum miR-146a inversely correlated with pro‐
teinuria and the SLE Disease Activity Index, which suggested that that both miR-146a and
miR-155 participated in the pathophysiology of SLE and might be used as biomarkers of
SLE [44]. The same authors recently confirmed that urinary levels of miR-146a and miR-155
in patients with SLE were significantly higher than that in healthy controls [45]. In another
study they also evidenced that the serum levels of miR-200a, miR-200b, miR-200c, miR-429,
miR-205 and miR-192, and urinary levels of miR-200a, miR-200c, miR-141, miR-429 and
miR-192 of SLE patients were lower than those of controls,with SLEDAI index that inversely
correlated with serum miR-200a [46]. Hai-yan et al. confirmed in their study the lower ex‐
pression of miR-146a in PBMCs of SLE patients compared to healthy controls [47].
In comparison with healthy controls, miR-21 and miR-148a [48] and miR-126 [42] resulted
up-regulated in SLE CD4+ T cells and promoted cell hypomethylation by repressing DNA
methyltransferase 1 (DNMT1) expression, which led to hypothsized that they contribute to
T cell autoreactivity in SLE.
Compared with controls, miR-21 has been also found upregulated in SLE CD4+ T lympho‐
cytes by Stagakis et al. [39]. MiR21 strongly correlated with SLE disease activity and investi‐
gation of putative gene-targets showed that it suppressed PDCD4, thus regulating aberrant
T cell responses in human SLE.
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Most recently, Ding et al. demonstrated that miR-142-3p/5p were significantly down-regulated
in SLE CD4+ T cells compared with healthy controls and that their reduced expression caused T
cell activity and B cell hyperstimulation[49]. Lu et al. showed a different intra-renal expression
of miR-638, miR-198 and miR-146a between LN patients and normal controls [38]. In particu‐
lar,  miR-638  had  lower  glomerular  expression  and  higher  tubulointerstitial  expression;
miR-198 resulted up-regulated in both glomerulus and in tubulointerstitium; and miR-146a
was overexpressed in glomerulus. Interestingly, tubulointerstitial miR-638 expression signifi‐
cantly correlated with clinical disease severity (estimated GFR/histological activity index and
proteinuria/disease activity score, respectively), while glomerular miR-146a expressions were
correlated with estimated GFR and histological activity index [38].
Main miRNA dysregulated in SLE are shown in Tab.1.
Up-regulated Down-regulated
-miR198 and miR21 (PBMC)[36]
-miR-371–5P,miR-423–5P, miR-638 and miR-663
(PBMC)[43]
-miR-21 and miR-148a (CD4+ T cells)[48]
-miR-21 (CD4+ T cells) [39]
-miR-126(CD4+ T cells)[42]
-miR-638, miR-198 and miR-146a (intra-renal) [38]
-miR-184 (PBMC) [36]
-miR-1224–3P (PBMC) [43]
- miR-31, miR-95, miR-99a, miR-130b, miR-10a, miR-134, and miR-
146a (PBMC) [40]
-miR-146a and miR-155 (serum) [44]
-miR-142-3p/5p (CD4+ T cells) [49]
-miR-638 (intra-renal) [38]
-miR-146a (urine)[44]
Abbreviations: PBMC, peripheral blood mononuclear cells
Table 1. Main microRNA dysregulated in SLE
2.1.2. Sjögren Syndrome (SS)
SS is  an  inflammatory  autoimmune disease  primarily  affecting  the  exocrine  glands  and
characterized by the presence of typical autoantibodies such as anti-Ro (SSA) and anti-La
(SSB),  keratoconjunctivitis  sicca,  xerostomia,  pulmonary involvement,  nonerosive polyar‐
thritis and increased risk of lymphoid malignancy [50].  The relatively easy access to the
target tissue (salivary glands and saliva) makes Sjogren's syndrome appealing to study mi‐
croRNAs [41]. Michael et al. demonstrated a prominent difference between miRNAs pro‐
file  in  saliva  obtained  from  patients  with  SS  and  healthy  donors  [51].  Alevizos  et  al.
showed a  different  miRNA expression profile  in  glands  of  SS  in  comparison with  con‐
trols. Moreover, in half of the patients with a focus score of 12, the miR-17-92 cluster re‐
sulted downregulated [52].
Lu et al. showed that miR-574 and miR-768-3p resulted overexpressed in the SS salivary
glands, while miRNA-146a was increased in PBMCs and salivary glands [53]. Interestingly,
the overexpression of miR146a was confirmed in PBMC of patients with SS [54, 55] as well
as in PBMCs and in the salivary glands of a SS mouse model [54]. These results are promis‐
ing for the development of future diagnostic and prognostic biomarkers in SS.
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Main miRNA dysregulated in SS are shown in Tab.2.
Up-regulated Down-regulated
-miR-574 and miR-768-3p (salivary glands) [53]
-miR-146a (PBMCs and salivary glands) [53]
-miR-146a (PBMCs) [54, 55]
miR-17-92 (salivary glands) [52]
Abbreviations: PBMC, peripheral blood mononuclear cells
Table 2. Main microRNA dysregulated in SS
2.1.3. Systemic Sclerosis (SSc)
SSc is a generalized connective tissue disease affecting skin and internal organs and charac‐
terized by abnormal extracellular collagen accumulation. It is tipically associated with spe‐
cific autoantibodies (anticentromere and anti-topoisomerase Scl-70) [56].
Recently, Maurer et al. found that miR-29a was strongly down-regulated in SSc fibroblasts
and skin sections as compared with the healthy controls and, similarly to human SSc, the
expression of miR-29a was reduced in the bleomycin model of skin fibrosis [57]. Interesting‐
ly, overexpression in SSc fibroblasts decreased, and knockdown in normal fibroblasts in‐
creased the levels of messenger RNA for type I and type III collagen, which highlighted the
role of miR-29a as post-transcriptional regulators of pro-fibrotic genes [57].These results ap‐
pear very intriguing and reveal that miR29 could be considered a potential therapeutic tar‐
get in SSc [57, 58]. In comparison with the normal skin tissues, Zhu et al. identified some
miRNAs aberrantly expressed in limited cutaneous scleroderma and diffuse cutaneous scle‐
roderma skin tissues, such as miR-21 (up-regulated) and miR-145 and miR-29b (down-regu‐
lated) both in the skin tissues and fibroblasto [59].
Main miRNA dysregulated in SSc are shown in Tab.3.
Up-regulated Down-regulated
-miR-21 (SSc skin tissues and fibroblasts)[59] -miR-29a (SSc fibroblasts) [57]
-miR-145 and miR-29b (SSc skin tissues and
fibroblasts) [59]
Table 3. Main microRNA dysregulated in SSc
2.2. Osteoarthritis (OA)
OA is the most common age related disorder whose main features are the damage of the articu‐
lar cartilage, the increased activity in the subchondral bone and osteophyte formation. A mod‐
erate synovitis may appear especially in advanced cases [60]. In comparison with normal
cartilage, Iliopoulos et al. evidenced 16 miRNAs differentially expressed in OA cartilage [61].
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Out of these, miR-22 resulted up-regulated and contributed to decreased expression of aggre‐
can and increased levels of IL-1b and MMP-13 in chondrocytes, while miR-140 was found
down-regulated and its under-expression was related to the development of age-related OA-
like changes [61]. In the cartilage of late-stage OA, Jones et al. described several differentially
expressed miRNAs, out of these miR-146a resulted down-regulated, miR-9 and miR-98 up-
regulated [62]. Interestingly, functional analysis revealed that miR-9 and miR-98 reduced the
IL-1β-induced production of  TNFα in primary chondrocytes,  while  miR-9 also inhibited
MMP-13 secretion in vitro, a scenario which led to hypothesized their protective role in OA
[62]. MiR-27a was also found down-regulated in OA chondrocytes and its underexpression in‐
directly inhibited MMP-13 and IGFBP-5 (insulin-like growth factor binding protein) [63]. A
protective role on OA cartilage and in modulating pain symptoms has been hypothesized for
miR-146A [64]. Most recently, overexpression of miR-146a, miR-155, miR-181a and miR-223
was demonstrated in  PBMCs of  OA patients  in  comparison with healthy controls,  with
miR-146a and miR-223 significantly higher in the early stages of OA than at later stages [65].
However, although several OA-associated miRNA have been reported to date, their potential
role in OA needs to be further elucidated and their targets need to be discovered in the future.
Main miRNA dysregulated in OA are shown in Tab.4
Up-regulated Down-regulated
-miR-22 (OA cartilage) [61]
-miR-9 and MiR-98 (OA cartilage) [62]
-miR-146a, miR-155, miR-181a (OA PBMCs) [65]
-miR-140 (OA cartilage) [61]
-miR-146a (OA cartilage) [62]
-miR-27a (OA chondrocytes) [63]
Abbreviations: PBMC, peripheral blood mononuclear cells
Table 4. Main microRNA dysregulated in OA
2.3. Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory joint disorder that is characterized by
immune-driven inflammation of synovial membrane which results in erosion, joint destruc‐
tion and disability. Extra-articular symptoms, such as serositis, nodules and vasculitis are
common and usually associated to a more severe disease. The etiology of rheumatoid arthri‐
tis (RA) is still unknown, and many uncertainties regarding its pathogenetic mechanisms
persist yet [66].
Many recent studies have demonstrated that different miRNAs are significantly dysregulat‐
ed in RA tissues.
2.3.1. Synovium
In comparison with healthy controls and/or OA patients, some miRNA have been found up-
(miR-155, miR-203 and miR-146a ) or down-(miR124a and miR-34a*) regulated in RA syno‐
vial tissue and/or synovial fluid [67-74].
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MiR-155  has  emerged as  one  of  the  most  attractive  and thoroughly  studied  miRNA in
RA.  It  was found significantly  up-regulated in  RA-synovial  fibroblasts  (RA-SFs)  [74],  in
the lining layer CD68+ macrophages [68] and in synovial fluid CD14+ cells [68, 74] of the
RA synovial compartment.
Since overexpression of miR-155 in RA-SFs was shown to decrease the levels of matrix met‐
alloproteinase 3 (MMP-3) and 1 (MMP-1) in vitro, it was initially hypothesized a protective
role of miR-155 by modulating destructive properties of RA-synovial fibroblasts (RA-SFs)
[74]. However, in vivo data have shown an opposite role for miR-155 in the development of
arthritis [68, 75]. Up-regulation of miR-155 in synovial fluid CD14+ cells increased the ex‐
pression of TNF-α, IL-1β, IL-6, and IL-8 and downregulated the expression of the miR-155
target SHIP-1 (Src homology 2-containing inositol phosphatase-1), an inhibitor of inflamma‐
tion [68], and miR-155-deficient mice are resistant to collagen-induced arthritis [75].These
data, together with the observation that specific inhibition of miR-155 in RA synovial macro‐
phages reduced TNF-alpha production led to ascribe to miR-155 a role in excessive proin‐
flammatory activation of myeloid cells in RA and to suggest that miR-155 may represent an
intriguing therapeutic target [68]. Interestingly, Worm et al. first reported on miR-155 silenc‐
ing in vivo in a mouse inflammation model [76], which further underlines the potentiality of
miR-155 antagonists as novel therapeutics for treatment of chronic inflammatory diseases.
MiR-203, was found significantly up-regulated in RA-SFs in comparison with OA-SFs [73]. It
resulted in higher release of MMP-1 and secretion of IL-6 via the NF-kappa B pathway,
which led to hypothesize a role in activating RA-SFs and triggering inflammation [73]. How‐
ever, the direct targets of miR-203 in RA-SFs still need to be highlighted [73].
Mir-146a resulted greatly expressed in RA synovial tissue when compared with OA and it
has been demonstrated in CD3+ T cells, IL-17 producing T cells, CD68+ cells, in some B lym‐
phocytes [70, 72, 74] and in RA-SF, where its expression resulted induced by several pro-in‐
flammatory mediators such as TNF-alpha and IL-1beta [70, 74]. However, its role in
synovial tissue has yet to be elucidate.
MiR-124a was found significantly lower in RA-SFs in comparison with OA [69]. Its down-regu‐
lation appears to play an important role in the pathogenesis of RA by mediating the enhance‐
ment of both cyclin-dependent kinase 2 (CDK-2), involved in the cell cycle regulation, and
monocyte chemoattractant protein 1 (MCP-1),which are able to attract into the synovial tissue
inflammatory cells, memory T lymphocytes and natural killer cells [67, 69]. These intriguing
findings have suggested that miR-124a could also have a therapeutic potential [67, 69].
Finally miR-34a* was found significantly down-regulated in RA-SFs in comparison with OA
as a result of higher DNA methylation, which would contribute to the RA-SFs resistance to
apoptosis, a typical feature of these RA cells [71]
2.3.2. Blood
MiR-146a was found overexpressed in PBMC obtained from RA patients, expecially those
with early RA and with high disease activity, compared with healthy and disease control in‐
dividuals [72, 77]. Other studies confirmed miR-146a overexpression in PBMC [78], in CD4+
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T lymphocytes from peripheral blood [79] and in plasma [80] of RA patients. The observa‐
tion that miR-146a was able to silence in PBMC the expression of interleukin-1 receptor-as‐
sociated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6), members of the
TLR4 signaling cascade [81], led to hypothesized that miR-146a could act as a negative regu‐
lator of inflammation, as supported by other recent studies [77, 82, 83]. However, in the
study of Pauley et al. PBMC expression of IRAK-1 and TRAF6 was no different between RA
patients and healthy controls, as expected [77], which led to hypothesized that was a defect
in regulation of these molecules by miR-146a that promoted inflammation, with an exten‐
sive and prolonged TNF-alpha production [77].
Consistent with the data on synovial compartment, miR-155 has been found increased in
PBMC from RA patients compared with healthy controls and upregulated during the differ‐
entiation of IL-17 producing cells [72, 77]. Conversely, concentrations of miR-155 and other
examined miRNA (miR-16, miR-132, miR-146a and miR-223) resulted not differently ex‐
pressed between RA and OA patients in plasma, although plasma levels of miR-155,miR-16,
miR-146a and miR-223 inversely correlated with clinical indices, such as tender joint count
and 28-joint Disease Activity Score (DAS 28).
Recently, Fulci et al showed a clear up-regulation of miR-223 and a significant downregula‐
tion of miR-142, miR-28 and miR-30e in T-lymphocytes from peripheral blood from RA pa‐
tients in comparison with healthy controls [84]. The same group confirmed the
overexpression of miR-223 in T-lymphocytes of early rheumatoid arthritis patients [85]
which led the authors to speculate that this aberrant over-expression could contribute to the
pathogenesis of the disease.
Other miRNAs resulted disregulated in RA, such as miR-16, miR-132, miR-26a, and miR-150
which resulted up-regulated in PBMC from patients with RA compared with healthy con‐
trols. [72, 77]. Of these, miR-16 and miR-150 correlated with disease activity [72, 77], where‐
as miR-26 and miR-150 resulted upregulated in IL-17 producing T cells [72].
Main miRNA dysregulated in RA are shown in Tab.5
Up-regulated Down-regulated
-miR-155 (synovium) [68, 74]
-miR-155 (PBMC) [72, 77]
-miR-203 (synovium) [73]
-miR-146a (synovium) [70, 72, 74]
-miR-146a (PBMC/ CD4+ T lymphocytes/plasma) [72,
77-80]
-miR-223 (blood T-lymphocytes [84, 85]
- miR-16, miR-132, miR-26a, and miR-150 (PBMC) [72,
77]
-miR-124a (synovium) [69]
-miR-34a* (synovium) [71]
Abbreviations: PBMC, peripheral blood mononuclear cells
Table 5. Main microRNA dysregulated in RA
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2.4. Psoriatic arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory disease that develops in ~ 20% of individ‐
uals with psoriasis [86]. PSA pathogenesis is not yet fully understood and lymphocytes, in
particular CD8+ T cells, appear to play an important role in the pathogenesis of both psoria‐
sis and PsA [87, 88]. In addition, several pro-inflammatory cytochines seem to be involved,
including TNF-α, IL-1, IL-6 and IL-12 [89-91]. While several studies have shown an altered
expression of miRNAs in psoriasis, to date – at the best of our knowledge - no studies have
been performed about the miRNA expression profile in PsA. On this background, we evalu‐
ated a comprehensive global miRNA expression profile in PBMCs of patients with PsA in
comparison with healthy controls, with the main purpose to characterise the miRNA signa‐
ture in PsA (Clin Drug Investig, in press). Below, the results of the principal studies on psoria‐
sis and the main results of our study on PsA are summarized.
2.4.1. Psoriasis
Several miRNA have been found disregulated in psoriatic skin when compared with
healthy skin, such as miR-203,miR-146a, miR-99a and miR-21 (up-regulated) or miR 125b
(down- regulated).
Up-regulation of miR-203 correlated with the underexpression of SOCS-3 (suppressor of cyto‐
kine signalling 3) which is implicated in inflammatory response and keratinocyte functions
[92]. Recently, Primo et al. confirmed the up-regulation of miR-203 in psoriatic lesions, with
TNF-alpha and IL24 as its direct targets [93]. The over-expressed miR-146a was related to the
TNF-α signalling control in the skin [94]. Up-regulation of miR-99a was correlated with a slow
keratinocyte proliferation and induction of their differentiation through regulation of IGF-1R
[95]. Elevated levels of miR-21 in psoriatic skin have been found by Meisgen et al. [96]. The au‐
thors evidenced that overexpression of this miRNA was related to apoptosis suppression in ac‐
tivated T cells, which contributed to T cell-derived psoriatic skin inflammation [96].
Downregulation of miR-125b has been associated with high TNF-α production [94] and with
the modulation of keratinocyte differentiation and proliferation by targeting FGFR2 (fibro‐
blast growth factor receptor 2) [97].
Other miRNA have been found dysregulated in psoriasis. Zibbert et al. identified 42 upre‐
gulated miRNAs and 5 downregulated miRNAs in psoriasis skin compared with healthy
skin [98]. Out of these, up-regulated miR-21, miR-205, miR-221 and miR-222 were found to
have potential mRNA targets in psoriatic skin such as PDCD4, TPM1, P57, C-KIT, RTN4,
SHIP2, TIMP3, RECK and NFIB, which were likely to be involved in cellular growth, prolif‐
eration, apoptosis and degradation of the extracellular matrix [98].
Down-regulation of miR-424 in the skin [99] and up-regulation of miR-1266 in the serum
[100] of PsA patients have also been demonstrated. Underexpression of miR-124 was re‐
lated  to  increased  levels  of  MEK1 or  cyclin  E1  proteins,  thus  to  enhanced  keratinocyte
proliferation  [99].  Overexpression  of  miR-1266  in  the  PsA serum was  quite  unexpected
being this miRNA a putative regulator of IL-17A, a key cytokine in PsA pathogenesis, so
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the authors hypothesized that miR-1266 could be involved in the pathogenesis of psoria‐
sis by regulating other target molecules [100].
Main miRNA dysregulated in psoriasis are shown in Tab.6.
Up-regulated Down-regulated
-miR-203 (psoriatic skin) [92, 93]
-miR-146a (psoriatic skin) [92]
-miR-99a (psoriatic skin) [95]
-miR-21 (psoriatic skin) [96]
-miR-21, miR-205, miR-221 and miR-222 ( psoriatic
skin)[98]
-miR-1266 (serum) [100]
-miR 125b (psoriatic skin) [92]
-miR-424 (psoriatic skin) [99]
Table 6. Main microRNA dysregulated in Psoriasis
2.4.2. Psoriatic arthritis
In our recent study (Clin Drug Investig, in press), we evaluated global miRNA expression profile
in PBMCs of 13 patients with early active and untreated PsA. In comparison with healthy con‐
trols, the PBMC of PsA group revealed the presence of 9 up-modulated and 7 down-regulated
miRNAs. Within the group of up-regulated, miR-21, miR-34a and miR-125a appeared of par‐
ticular interest considering the extent of their modulation and their emerging role in inflamma‐
tory processes (Clin Drug Investig,  in press)  (Tab.7).  Instead, all  down-regulated miRNAs
belonged to two large adjacent miRNA clusters located on chromosome 14, which makes this
chromosome worthy of further investigation in the field of psoriasis and PsA genetic suscepti‐
bility (Clin Drug investig, in press). Quantitative RT-PCR (RT-qPCR) analysis for specific miR‐
NA (miR-21, miR-34a, miR-125a), performed in the entire series of 13 PsA patients plus 5
additional PsA patients and in healthy controls, confirmed the up-regulation of these three
miRNA (unpublished data). (Figure 1A-C). Moreover, based on its emerging role in immunity
control and the proved involvement in other autoimmune diseases [40, 77, 81, 101, 102] we also
evaluated by RT-qPCR miR-146a levels in the entire group of 18 PsA patients. Also in this case,
real time results were in agreement with microarray and did not show significant differences
between patients and controls (unpublished data) (Figure 1D). The demonstration of a miRNA
signature in PsA could be a novel starting point for understanding pathogenic mechanisms of
this disease. Moreover, altered miRNAs expression in patients with active disease makes them
attractive as potential biomarkers of disease.
Up-regulated Down-regulated
MiR-21, miR-34a and miR-125a (PBMC) (Ciancio et al., Clin
Drug Investig,in press)
Abbreviations: PBMC, peripheral blood mononuclear cells
Table 7. Main microRNA dysregulated in PsA
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Figure 1. Validation of miR-34a (A), miR-21 (B), miR-125a (C) and miR-146a (D) levels by quantitative RT-PCR.
MiRNAs expression in 18 PsA patients and 8 controls was quantified using RT-qPCR. Each expression data was normal‐
ized on endogenous U6 RNA level by 2-∆Ct method. Each sample was analyzed in triplicate. Data are displayed using
vertical scatter plot (GraphPad v.5), bars represent means ± SEM. Two-tailed t-test was used to determine the p-values.
3. Conclusions
MiRNA are fine regulators of gene expression at the post-trascriptional level and it is to‐
day known that they partecipate in the regulation of almost every aspect of cell physiol‐
ogy,  including  the  development  of  immune  cells  and  the  regulation  of  the  immune
response.
MiRNA altered expression has been related to the development of several chronic inflam‐
matory and autoimmune diseases such as systemic lupus erithematosus,  rheumatoid ar‐
thritis,  Sjogren  syndrome,  systemic  sclerosis,  psoriasis  and  psoriatic  arthritis.
Osteoarthritis,  the most common age related disorder,  seems also to be related to an al‐
tered expression of  miRNAs.  Besides their  crucial  role in the pathogenesis  of  rheumatic
diseases,  miRNAs can also be predictive of disease activity and severity,  helpful as bio‐
markers and useful for development of new therapeutic strategies. However, this exciting
field of research is still at an early stage and larger studies are still desirable to define the
specific roles that individual miRNAs may play in rheumatic diseases.
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